H.C. Wainwright analyst Robert Burns lowered the firm’s price target on BioNTech (BNTX) to $134 from $145 and keeps a Buy rating on the shares following the Q1 report. The firm is factoring in higher operating expenses moving forward.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Prasad appointment not necessarily bad news for biopharma, says Citi
- Strategic Importance of BioNTech’s COVID-19 Vaccine and Oncology Ambitions Drive Buy Rating
- BioNTech SE: Promising Oncology Pipeline and Strategic Trials Justify Buy Rating
- BioNTech price target lowered to $140 from $145 at Citi
- BioNTech SE Reports Q1 2025 Financial Results